220 related articles for article (PubMed ID: 21835955)
1. The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.
Dale DC; Bolyard AA; Kelley ML; Westrup EC; Makaryan V; Aprikyan A; Wood B; Hsu FJ
Blood; 2011 Nov; 118(18):4963-6. PubMed ID: 21835955
[TBL] [Abstract][Full Text] [Related]
2. The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome.
McDermott DH; Liu Q; Ulrick J; Kwatemaa N; Anaya-O'Brien S; Penzak SR; Filho JO; Priel DA; Kelly C; Garofalo M; Littel P; Marquesen MM; Hilligoss D; Decastro R; Fleisher TA; Kuhns DB; Malech HL; Murphy PM
Blood; 2011 Nov; 118(18):4957-62. PubMed ID: 21890643
[TBL] [Abstract][Full Text] [Related]
3. Clinical and genetic features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) syndrome.
Dotta L; Tassone L; Badolato R
Curr Mol Med; 2011 Jun; 11(4):317-25. PubMed ID: 21506920
[TBL] [Abstract][Full Text] [Related]
4. Plerixafor for the Treatment of WHIM Syndrome.
McDermott DH; Pastrana DV; Calvo KR; Pittaluga S; Velez D; Cho E; Liu Q; Trout HH; Neves JF; Gardner PJ; Bianchi DA; Blair EA; Landon EM; Silva SL; Buck CB; Murphy PM
N Engl J Med; 2019 Jan; 380(2):163-170. PubMed ID: 30625055
[TBL] [Abstract][Full Text] [Related]
5. A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome.
McDermott DH; Velez D; Cho E; Cowen EW; DiGiovanna JJ; Pastrana DV; Buck CB; Calvo KR; Gardner PJ; Rosenzweig SD; Stratton P; Merideth MA; Kim HJ; Brewer C; Katz JD; Kuhns DB; Malech HL; Follmann D; Fay MP; Murphy PM
J Clin Invest; 2023 Oct; 133(19):. PubMed ID: 37561579
[TBL] [Abstract][Full Text] [Related]
6. A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor.
McDermott DH; Liu Q; Velez D; Lopez L; Anaya-O'Brien S; Ulrick J; Kwatemaa N; Starling J; Fleisher TA; Priel DA; Merideth MA; Giuntoli RL; Evbuomwan MO; Littel P; Marquesen MM; Hilligoss D; DeCastro R; Grimes GJ; Hwang ST; Pittaluga S; Calvo KR; Stratton P; Cowen EW; Kuhns DB; Malech HL; Murphy PM
Blood; 2014 Apr; 123(15):2308-16. PubMed ID: 24523241
[TBL] [Abstract][Full Text] [Related]
7. A WHIM satisfactorily addressed.
Broxmeyer HE
Blood; 2014 Apr; 123(15):2286-8. PubMed ID: 24723677
[TBL] [Abstract][Full Text] [Related]
8. Genetics on a WHIM.
Al Ustwani O; Kurzrock R; Wetzler M
Br J Haematol; 2014 Jan; 164(1):15-23. PubMed ID: 24111611
[TBL] [Abstract][Full Text] [Related]
9. Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration.
De Clercq E
Antivir Chem Chemother; 2019; 27():2040206619829382. PubMed ID: 30776910
[TBL] [Abstract][Full Text] [Related]
10. Released on a WHIM.
Diaz GA
Blood; 2011 Nov; 118(18):4764-5. PubMed ID: 22053172
[No Abstract] [Full Text] [Related]
11. AMD3100 is a potent antagonist at CXCR4(R334X) , a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome.
McDermott DH; Lopez J; Deng F; Liu Q; Ojode T; Chen H; Ulrick J; Kwatemaa N; Kelly C; Anaya-O'Brien S; Garofalo M; Marquesen M; Hilligoss D; DeCastro R; Malech HL; Murphy PM
J Cell Mol Med; 2011 Oct; 15(10):2071-81. PubMed ID: 21070597
[TBL] [Abstract][Full Text] [Related]
12. Defect of plasmacytoid dendritic cells in warts, hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome patients.
Tassone L; Moratto D; Vermi W; De Francesco M; Notarangelo LD; Porta F; Lougaris V; Facchetti F; Plebani A; Badolato R
Blood; 2010 Dec; 116(23):4870-3. PubMed ID: 20736454
[TBL] [Abstract][Full Text] [Related]
13. Tetralogy of fallot is an uncommon manifestation of warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
Badolato R; Dotta L; Tassone L; Amendola G; Porta F; Locatelli F; Notarangelo LD; Bertrand Y; Bachelerie F; Donadieu J
J Pediatr; 2012 Oct; 161(4):763-5. PubMed ID: 22748845
[TBL] [Abstract][Full Text] [Related]
14. Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome.
Dale DC; Firkin F; Bolyard AA; Kelley M; Makaryan V; Gorelick KJ; Ebrahim T; Garg V; Tang W; Jiang H; Skerlj R; Beaussant Cohen S
Blood; 2020 Dec; 136(26):2994-3003. PubMed ID: 32870250
[TBL] [Abstract][Full Text] [Related]
15. WHIM syndrome: Immunopathogenesis, treatment and cure strategies.
McDermott DH; Murphy PM
Immunol Rev; 2019 Jan; 287(1):91-102. PubMed ID: 30565238
[TBL] [Abstract][Full Text] [Related]
16. Plerixafor on a WHIM - Promise or Fantasy of a New CXCR4 Inhibitor for This Rare, but Important Syndrome?
Merati N; Sivachandran S; Jfri A; Ben-Shoshan M; Vinh DC; Popradi G; Litvinov IV
Skin Therapy Lett; 2022 Mar; 27(2):1-5. PubMed ID: 35385630
[TBL] [Abstract][Full Text] [Related]
17. CXCL12/CXCR4-axis dysfunctions: Markers of the rare immunodeficiency disorder WHIM syndrome.
Bachelerie F
Dis Markers; 2010; 29(3-4):189-98. PubMed ID: 21178277
[TBL] [Abstract][Full Text] [Related]
18. Cerebellar involvement in warts Hypogammaglobulinemia immunodeficiency myelokathexis patients: neuroimaging and clinical findings.
Galli J; Pinelli L; Micheletti S; Palumbo G; Notarangelo LD; Lougaris V; Dotta L; Fazzi E; Badolato R
Orphanet J Rare Dis; 2019 Feb; 14(1):61. PubMed ID: 30819232
[TBL] [Abstract][Full Text] [Related]
19. Severe CD8+ T Lymphopenia in WHIM Syndrome Caused by Selective Sequestration in Primary Immune Organs.
Majumdar S; Pontejo SM; Jaiswal H; Gao JL; Salancy A; Stassenko E; Yamane H; McDermott DH; Balabanian K; Bachelerie F; Murphy PM
J Immunol; 2023 Jun; 210(12):1913-1924. PubMed ID: 37133343
[TBL] [Abstract][Full Text] [Related]
20. WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12.
Balabanian K; Lagane B; Pablos JL; Laurent L; Planchenault T; Verola O; Lebbe C; Kerob D; Dupuy A; Hermine O; Nicolas JF; Latger-Cannard V; Bensoussan D; Bordigoni P; Baleux F; Le Deist F; Virelizier JL; Arenzana-Seisdedos F; Bachelerie F
Blood; 2005 Mar; 105(6):2449-57. PubMed ID: 15536153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
